LAVAL, Quebec, Nov. 29, 2016 /CNW/ -- Valeant
Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX)
("Valeant") today announced that it has initiated a significant
sales force expansion to focus on potential primary care physician
(PCP) prescribers of Xifaxan for irritable bowel syndrome with
diarrhea (IBS-D) and Relistor for opioid induced constipation
(OIC.) With the launch of the expanded sales force effort
over the coming weeks, the company expects to reach a significant
majority of likely Xifaxan and Oral Relistor primary care
prescribers. The costs of this program were considered in
previously announced guidance for the full year 2016.
"Our goal in building a primary care sales force is to maximize
opportunities for Xifaxan and Relistor to help our products reach
full potential. Xifaxan and Relistor are integral to our
gastrointestinal franchise which remains a core asset for future
growth potential in the hands of Valeant," said Joseph C. Papa, chairman and chief executive
officer. "With approximately 70% of IBS-D patients initially
presenting with symptoms to a primary care physician, our dedicated
PCP sales force will be better able to reach the patients in need
of IBS-D treatment and in doing so will further advance our mission
to improve people's lives with our healthcare products."
About Valeant
Valeant Pharmaceuticals International,
Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical
company that develops, manufactures and markets a broad range of
pharmaceutical products primarily in the areas of dermatology,
gastrointestinal disorders, eye health, neurology and branded
generics. More information about Valeant can be found at
www.valeant.com.
Forward-looking Statements
This press release may
contain forward-looking statements which may generally be
identified by the use of the words "anticipates," "expects,"
"intends," "plans," "should," "could," "would," "may," "will,"
"believes," "estimates," "potential," "target," or "continue" and
variations or similar expressions. These statements are based upon
the current expectations and beliefs of management and are subject
to certain risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. These risks and uncertainties include, but are not
limited to, risks and uncertainties discussed in the Company's most
recent annual or quarterly report and detailed from time to time in
Valeant's other filings with the Securities and Exchange Commission
and the Canadian Securities Administrators, which factors are
incorporated herein by reference. Readers are cautioned not to
place undue reliance on any of these forward-looking
statements. These forward-looking statements speak only as of
the date hereof. Valeant undertakes no obligation to update any of
these forward-looking statements to reflect events or circumstances
after the date of this press release or to reflect actual outcomes,
unless required by law.
Contact Information:
Elif McDonald
elif.mcdonald@valeant.com
514-856-3855
877-281-6642 (toll free)
Media:
Renée Soto
or
Chris Kittredge/Jared Levy
Sard Verbinnen & Co.
212-687-8080
Logo -
http://photos.prnewswire.com/prnh/20101025/LA87217LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/valeant-announces-the-initiation-of-a-primary-care-sales-force-for-xifaxan-and-relistor-300369978.html
SOURCE Valeant Pharmaceuticals International, Inc.